Make your own free website on

Covixyl-V Nasal Spray Reviews:

A component of Covixyl TM prevents the virus from adhering to nasal tissue, thereby lowering the viral load in the tissue milieu. The nasal spray captures, inactivates, and aids in the natural removal of the virus as it takes root and begins to mature in the nasal passages, lowering the chance of infection. To confirm the in vitro and in vivo research carried out by Salvacion USA Inc., CovixylTM has successfully completed human clinical trials. We worked with the National Cancer Institute (NCI), an organisation under the National Institutes of Health (NIH), and were chosen to receive a Cascade Assay grant for CovixylTM nasal spray from the NCI in June 2021.

Mechanism of Action:

COVIXYL-V eliminates the virus by inhibiting it in the nasal tissues (if the virus does not attach, it is washed away by mucous secretions). By blowing one’s nose or producing typical nasal secretions, it assists in the natural removal of the inactivated virus. The active ingredient in COVIXYL-V, Ethyl LauroylArginate Hydrochloride (ELAH), is a Generally Recognized as Safe (GRAS) component approved by the Food and Drug Administration (FDA) for use in food and other over-the-counter goods in the US, EU, UK, and Germany.

Clinical Research:

The rVSV-SARS-CoV-2 model used in in vitro research revealed that the virus is 99.99% suppressed at low dosages. COVID-19 is 99.99% inactivated, according to in vivo research conducted by a BSL-3 facility utilising the Syrian hamster model, the same animal used by Pfizer and Modena for vaccine development, and no side effects were noticed after injection.

Three steps for usage:

Spray: Give each nostril two to three sprays. The ELAH formulation (Ethyl LauroylArginate HCL) prevents viral attachment to the nasopharynx, limiting virus growth and spread. Remove: The inactivated virus goes spontaneously from the nasopharynx outward to the nose or inward to the stomach due to the action of natural secretion. The nasal spray functions by creating a physical barrier that prevents the virus from adhering to the nasopharynx’s surface. In vitro testing conducted by a renowned BSL-3 facility located in Wyoming has proven this barrier mechanism.

Since the nasopharynx has been identified as the primary entrance site for the virus, using the nasal spray is mostly effective. The unique COVIXYL-V technology has been submitted as a PCT international patent (PT/US20/55772). Numerous in vitro and in vivo studies have been conducted on ELAH to determine its toxicity, metabolism, and efficiency. These studies verified that it has no adverse effects on the human body in terms of metabolism, pharmacology, or immunology. This product is awaiting FDA clearance for commercial use in the United States after being filed for pre-emergency use authorization.

How does CovixylTM work?

Most respiratory viruses enter the body through the nose, where they adhere and start replicating on nasal cells. For up to six (6) hours after usage, CovixylTM shields the body against infection by forming a physical barrier in the nasopharynx that inhibits airborne respiratory viruses from adhering to the cell walls. This impact was shown by our scanning electron microscopy at the University of Wyoming. After an incubation period during which cells were first treated with CovixylTM and then infected with the virus, the control group’s cells saw virions emerging from them, suggesting infection and reproduction. This behaviour was absent in the treated cells, demonstrating an absence of infection.

Can anybody use CovixylTM?

For those over the age of 12, CovixylTM has been clinically shown to be both safe and effective. Before taking CovixylTM, anybody under the age of 12 or a woman who is pregnant or nursing should speak with a doctor. The results of the experiment indicated that the treated cells had no signs of infection, showing that CovixylTM was successful in preventing any invasion.

Does using CovixylTM mean I do not need a vaccine?

CovixylTM is intended to work in conjunction with other health officials’ recommended mitigating strategies in addition to immunisations. For defence against respiratory infections that are spread through the air, we do not advise depending entirely on CovixylTM.

Intellectual property rights

Any intellectual property rights, such as copyrights, trademark rights, patent rights, and design rights associated with this application, are the sole property of the owner or its licensors and are subject to the protection provided by applicable laws or international agreements relating to intellectual property, without limiting any other specific provision of these Terms. All trademarks, whether nominal or figurative, as well as any other marks, trade names, service marks, word marks, illustrations, images, or logos used in connection with this application are and will remain the sole property of their respective owners or licensors and are protected by any applicable laws or agreements on intellectual property.

For More Info:


Leave a Reply

Your email address will not be published. Required fields are marked *